Nippon Shinyaku has scheduled its next earnings announcement for 13 November 2026. According to the summary of its financial results, revenue increased 22.8% year on year to ¥97.83 billion, while operating profit was ¥19.27 billion.
Nippon Shinyaku has scheduled its next earnings announcement for 13 November 2026. Information on the financial results announcement schedule has been provided.
According to the summary of its financial results, revenue was ¥97.83 billion, up 22.8% year on year. Operating profit fell 1.6% year on year to ¥19.27 billion due to increases in selling, general and administrative expenses and research and development expenses.
Profit before tax for the interim period was ¥20 billion, while interim profit attributable to owners of the parent was ¥15.47 billion. Both were below the year-earlier levels. Performance over the past 12 quarters is viewed as slightly soft and broadly flat.
The five points identified for monitoring future performance are growth in sales of key drug products, the impact of changes in the timing of Erleada revenue recognition, increased sales of functional foods, progress on additional indications and applications, and expansion through licensing agreements. Risk factors include delays in the launch of CAP-1002, constraints on the review and clinical trials of gene therapies, higher research and development expenses, the impact of drug price revisions and generic products, and preparations for patent expiries.